Candidate Compounds Covid19

Aus coViki
(Unterschied zwischen Versionen)
Wechseln zu: Navigation, Suche
K
 
(15 dazwischenliegende Versionen von einem Benutzer werden nicht angezeigt)
Zeile 1: Zeile 1:
{{pnc}}
+
{{gohome}}
 +
{{ft|P}}
 +
  '''CHERRYPICKING STUDIES IS NOT SCIENCE
 +
{{qt|Reviews on covid drug development}}
  
current items will be put into the subsections.
 
  
*[[reviews on covid drug development]]
+
*'''[[scouting ideas]]'''
*[[scouting ideas]]
+
  
*[[Patients on biologicals]]
+
*'''[[PHA Biologicals]]'''
*[[HMGB1, RAGE]]
+
*[[pre-Interleukin 6]]
+
*[[post-Interleukin 6]]
+
*[[pre-TNFalpha]]
+
*[[post-TNFalpha]]
+
*[[pre-Interleukin 17]]
+
*[[post-Interleukin 17]]
+
*[[pre-Interleukin 1]]
+
*[[post-Interleukin 1]]
+
*[[Inflammasome]] ''colchicine''
+
*[[Methotrexate]]
+
*[[other anti-inflammatory]]
+
*[[NK-kappaB]]
+
*[[STAT 3]]
+
*[[JAK Janus Kinase]]
+
*[[Corticosteroids]]
+
*[[Cytokine absorbers]]
+
*[[Target Complement system]]
+
*[[Target Extracellular traps]]
+
*[[Target Neurophils]]
+
*[[Target Mast cells]] and kinins
+
*[[TGF beta]]
+
*[[Immunosuppressants]]
+
*[[Anticoagulant in covid19]]
+
*[[Antioxidants]]
+
*[[HIF-EPO-Iron]]
+
*[[Stem cells]]
+
*[[MDSC cells]]
+
*[[Interferons]]
+
*[[cAMP cGMP PDE NO]]
+
*[[TRPV* channels]]
+
*[[Retinoids]]
+
*[[Protease inhibitors]]
+
*[[Tyrosine kinase inhibitors]]
+
*[[Antineoplastic agents, traditional]]
+
*[[Mouthrinses]]
+
*[[Adenosinergic signaling]]
+
*[[Purinergic signaling]]
+
*[[Nicotinergic signaling]]
+
  
 +
*'''[[PHA conventional pharmacology]]'''
  
*[[other single compounds]]
+
*'''[[PHA retargeted compounds]]'''
*[[Retargeted Psychopharm]]
+
*[[Hydroxychloroquine]]
+
*
+
*[[Target ACE2, Spike protein]]
+
*[[Target TMPRSS2, Spike protein]] ''any other covid targed herein''
+
*[[other antiviral compounds]]
+
*[[AV Remdesivir]]
+
*[[AV Lopinavir]]
+
*[[AV Ivermectin]]
+
*[[AV Arabidol]]
+
*[[AV Favipiravir]]
+
  
*[[Antibiotics]]
+
*'''[[PHA antivirals by mechanism]]'''
  
 +
*'''[[PHA pharmacophore by screened target]]'''
  
*[[Vitamin D]]
+
*'''[[PHA ImmunoNutrients]]
*[[Anorganic nutrients Magnesium]]
+
*[[Anorganic nutrients Selenium]]
+
*[[Anorganic nutrients Zinc]]
+
*[[Anorganic nutrients Lithium]]
+
*[[Anorganic nutrients Copper]]
+
*[[Anorganic nutrients Bismuth]]
+
*[[Nutrition, general]]
+
*[[Exercise, Vibration]]
+
  
 +
*'''[[PHA compl altern natural]]'''
  
*[[Traditional Chinese Medicine]]
+
*'''[[PHA within indications compounds]]'''
*[[Natural compounds]]
+
  
*[[Statins]]
+
*'''[[PHA Serum products]]'''
*[[Antidiabetic compounds, any]]
+
*[[RSP - On RAS drugs]]
+
*[[RSP - On NSAIDs]]
+
  
*[[Reconvalescent blood products, Passive vaccine]]  
+
*'''[[PHA Vaccination]]'''
*[[Plasmapheresis]]
+
 
 +
PHA related options:
  
*[[Immunodeviation]] e.g. by adjuvants or other vaccinations
 
 
*[[Radiation therapy]]
 
*[[Radiation therapy]]
 
*[[Phototherapy]]
 
*[[Phototherapy]]
*[[Active vaccine]]  
+
*[[Electric fields]]
 
+
 
*[[Treatment other concepts]]
 
*[[Treatment other concepts]]
----
 
  
  
{{tp|p=32628145|t=2020. Blocking angiotensin earlier with RAS blockers, statins, and heparin in high-risk COVID-19 patients: Is the remedy here?|pdf=|usr=012}}
+
A concept of curative retargeting has been found by cellular lockdown with kinase inhibitors from the oncologic pharmacopoiea.
{{tp|p=32634024|t=2020. How to Quantify and Interpret Treatment Effects in Comparative Clinical Studies of COVID-19.|pdf=|usr=012}}
+
This means, virus replication can be stalled to zero w/o need of develpoment of new substances. There is no need for world
{{tp|p=32646061|t=2020. Could Ergothioneine Aid in the Treatment of Coronavirus Patients?|pdf=|usr=012}}
+
vaccination anymore. The virus needs permissible cells, and most perimissible is phosphotyrosine on its own compnents.
{{tp|p=32638906|t=2020. Controle do Intervalo QT para Prevencao de Torsades de Pointes Durante uso de Hidroxicloroquina e/ou Azitromicina em Pacientes com COVID 19.|pdf=|usr=012}}
+
Paper is (not yet in PubMed) :
{{tp|p=32645994|t=2020. Ten-Year Research Update Review: Antiviral Activities from Marine Organisms.|pdf=|usr=012}}
+
 
{{tp|p=32649880|t=2020. Need for Speed: From Human SARS-CoV-2 Samples to Protective and Efficacious Antibodies in Weeks.|pdf=|usr=012}}
+
*'''[https://www.sciencedirect.com/science/article/pii/S1097276520305499?via%3Dihub Growth factor receptor signaling inhibition prevents SARS-CoV-2 replication at Mol Cell 2020/08/11]'''
{{tp|p=32641681|t=2020. Is hydroxychloroquine beneficial for COVID-19 patients?|pdf=|usr=012}}
+
credentials to [https://web.de/magazine/news/coronavirus/coronavirus-blockade-zellulaerer-kommunikation-forscher-stoppen-vermehrung-sars-cov-2-35045170 Marinus Brandl] who told us about it today.
{{tp|p=32638908|t=2020. Double-edged sword: Granulocyte colony stimulating factors in cancer patients during the COVID-19 era.|pdf=|usr=012}}
+
based on e.g.
{{tp|p=32646869|t=2020. Challenges in evaluating SARS-CoV-2 vaccines during the COVID-19 pandemic.|pdf=|usr=012}}
+
 
{{tp|p=32646499|t=2020. Effect of favipiravir and an anti-inflammatory strategy for COVID-19.|pdf=|usr=012}}
+
{{ttp|p=32408336|t=2020. Proteomics of SARS-CoV-2-infected host cells reveals therapy targets |pdf=|usr=}}
{{tp|p=32631373|t=2020. Clarifying the controversial risk-benefit profile of soluble ACE2 in COVID-19.|pdf=|usr=012}}
+
{{tp|p=32620147|t=2020. Nafamostat mesylate treatment in combination with favipiravir for patients critically ill with Covid-19: a case series.|pdf=|usr=012}}
+
{{tp|p=32618691|t=2020. A Centrally Acting Antihypertensive, Clonidine, Sedates Patients Presenting With Acute Respiratory Distress Syndrome Evoked by Severe Acute Respiratory Syndrome-Coronavirus 2.|pdf=|usr=012}}
+
{{tp|p=32640414|t=2020. Vitamin D deficiency in patients with diabetes and COVID- 19 infection.|pdf=|usr=012}}
+
{{tp|p=32634717|t=2020. Application of Artificial Intelligence in COVID-19 drug repurposing.|pdf=|usr=012}}
+
{{tp|p=32639233|t=2020. Concentration-dependent mortality of chloroquine in overdose.|pdf=|usr=012}}
+
{{tp|p=32619390|t=2020. Shotgun proteomics analysis of SARS-CoV-2-infected cells and how it can optimize whole viral particle antigen production for vaccines.|pdf=|usr=012}}
+
{{tp|p=32615862|t=2020. Profiles of COVID-19 clinical trials in the Chinese Clinical Trial Registry.|pdf=|usr=012}}
+
{{tp|p=32616599|t=2020. Potential of regulatory T cell-based therapies in the management of severe COVID-19.|pdf=|usr=012}}
+
{{tp|p=32640331|t=2020. Analysis of the intricate effects of polyunsaturated fatty acids and polyphenols on inflammatory pathways in health and disease.|pdf=|usr=012}}
+
{{tp|p=32621202|t=2020. Use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in context of COVID-19 outbreak: a retrospective analysis.|pdf=|usr=012}}
+
{{tp|p=32638628|t=2020. Research progress on repositioning drugs and specific therapeutic drugs for SARS-CoV-2.|pdf=|usr=012}}
+
{{tp|p=32622993|t=2020. Prophylactic (hydroxy)chloroquine in COVID-19: potential relevance for cardiac arrhythmia risk.|pdf=|usr=012}}
+
{{tp|p=32621881|t=2020. INCIDENCE OF ARRHYTHMIAS AND ELECTROCARDIOGRAPHIC ABNORMALITIES IN SYMPTOMATIC PEDIATRIC PATIENTS WITH PCR POSITIVE SARS-CoV-2 INFECTION INCLUDING DRUG INDUCED CHANGES IN THE CORRECTED QT INTERVAL (QTc).|pdf=|usr=012}}
+
{{tp|p=32641876|t=2020. Curcumin: a Wonder Drug as a Preventive Measure for COVID19 Management.|pdf=|usr=012}}
+
{{tp|p=32641874|t=2020. Hydroxychloroquine and Covid-19: A Cellular and Molecular Biology Based Update.|pdf=|usr=012}}
+
{{tp|p=32643111|t=2020. Povidone-Iodine Demonstrates Rapid In Vitro Virucidal Activity Against SARS-CoV-2, The Virus Causing COVID-19 Disease.|pdf=|usr=012}}
+
{{tp|p=32640381|t=2020. Identification of potential inhibitors against SARS-CoV-2 by targeting proteins responsible for envelope formation and virion assembly using docking based virtual screening, and pharmacokinetics approaches.|pdf=|usr=012}}
+
{{tp|p=32642806|t=2020. Baricitinib as rescue therapy in a patient with COVID-19 with no complete response to sarilumab.|pdf=|usr=012}}
+
{{tp|p=32645633|t=2020. An update on antiviral antibody-based biopharmaceuticals.|pdf=|usr=012}}
+
{{tp|p=32645632|t=2020. Baricitinib, a drug with potential effect to prevent SARS-COV-2 from entering target cells and control cytokine storm induced by COVID-19.|pdf=|usr=012}}
+
{{tp|p=32634603|t=2020. COVID-19 Treatment: Close to a Cure? - A Rapid Review of Pharmacotherapies for the Novel Coronavirus.|pdf=|usr=012}}
+
{{tp|p=32646770|t=2020. Clinical characteristics and predictors of survival in adults with coronavirus disease 2019 receiving tocilizumab.|pdf=|usr=012}}
+
{{tp|p=32639711|t=2020. CNS Penetration Ability: A Critical Factor for Drugs in the Treatment of SARS-CoV-2 Brain Infection.|pdf=|usr=012}}
+
{{tp|p=32619190|t=2020. Passive immunization: Paradoxical and traditional method for new pandemic challenge COVID-19.|pdf=|usr=012}}
+
{{tp|p=32648245|t=2020. COVID-19 and Mesenchymal Stem Cell Treatment; Mystery or Not.|pdf=|usr=012}}
+
{{tp|p=32628223|t=2020. Very Long-acting Antivirals as Chemovaccines for Preventing Viral Infections.|pdf=|usr=012}}
+
{{tp|p=32640172|t=2020. Poly(ADP-ribose) Polymerase Inhibition in Acute Lung Injury: A Re-emerging Concept.|pdf=|usr=012}}
+
{{tp|p=32634026|t=2020. COVID-19 Clinical Trials: Unravelling a Methodological Gordian Knot.|pdf=|usr=012}}
+
{{tp|p=32628535|t=2020. Regulatory T Cells for Treating Patients With COVID-19 and Acute Respiratory Distress Syndrome: Two Case Reports.|pdf=|usr=012}}
+
{{tp|p=32647027|t=2020. Interleukin-6 receptor blockade with subcutaneous tocilizumab in severe COVID-19 pneumonia and hyperinflammation: a case-control study.|pdf=|usr=012}}
+
{{tp|p=32632035|t=2020. Serological tests confirm the low incidence of COVID-19 in chronic rheumatic inflammatory diseases treated with biological DMARD.|pdf=|usr=012}}
+
{{tp|p=32632034|t=2020. COVID-19 in paediatric rheumatology patients treated with b/tsDMARDs: a cross-sectional patient survey study.|pdf=|usr=012}}
+
{{tp|p=32632030|t=2020. Response to: 'COVID-19 in paediatric rheumatology patients treated with b/tsDMARDs: a cross-sectional patient survey study' by Cuceoglu et al.|pdf=|usr=012}}
+
{{tp|p=32620597|t=2020. Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study.|pdf=|usr=012}}
+
{{tp|p=32641296|t=2020. Effect of Systemic Inflammatory Response to SARS-CoV-2 on Lopinavir and Hydroxychloroquine Plasma Concentrations.|pdf=|usr=012}}
+
{{tp|p=32631826|t=2020. Clinical trials of repurposed antivirals for SARS-CoV-2.|pdf=|usr=012}}
+
{{tp|p=32639103|t=2020. Trainee Led Collaboratives, Clinical Trials And New Opportunities In The Covid-19 Era.|pdf=|usr=012}}
+
{{tp|p=32644876|t=2020. Nutrients in prevention, treatment, and management of viral infections; special focus on Coronavirus.|pdf=|usr=012}}
+
{{tp|p=32646867|t=2020. Vaccines, convalescent plasma, and monoclonal antibodies for covid-19.|pdf=|usr=012}}
+
{{tp|p=32631851|t=2020. Urgent call for greater multilateralism and coordination of covid-19 trials.|pdf=|usr=012}}
+
{{tp|p=32631850|t=2020. Covid-19: research methods must be flexible in a crisis.|pdf=|usr=012}}
+
{{tp|p=32620554|t=2020. Dexamethasone in the management of covid -19.|pdf=|usr=012}}
+
{{tp|p=32611587|t=2020. Covid-19: Lopinavir-ritonavir does not benefit hospitalised patients, UK trial finds.|pdf=|usr=012}}
+
{{tp|p=32641344|t=2020. COVID-19 clinical trials: see it big and keep it simple.|pdf=|usr=012}}
+
{{tp|p=32639062|t=2020. Serious adverse events with tocilizumab: pharmacovigilance as an aid to prioritize monitoring in COVID-19.|pdf=|usr=012}}
+
{{tp|p=32627226|t=2020. Potential role of IL-17 blocking agents in the treatment of severe COVID-19?|pdf=|usr=012}}
+
{{tp|p=32645204|t=2020. Double-bright (CD56bright/CD16bright) NK cell adoptive immunotherapy for SARS-CoV-2.|pdf=|usr=012}}
+
{{tp|p=32621754|t=2020. COVID-19 pandemic and management of GIMEMA clinical trials: changes and challenges.|pdf=|usr=012}}
+
{{tp|p=32639031|t=2020. Proteinase-activated receptor 1 (PAR1): A target for repurposing in the treatment of COVID-19?|pdf=|usr=012}}
+
{{tp|p=32640179|t=2020. Current Therapies Under Investigation for COVID-19.|pdf=|usr=012}}
+
{{tp|p=32633733|t=2020. Interaction of hydroxychloroquine with SARS-CoV2 functional proteins using all-atoms non-equilibrium alchemical simulations.|pdf=|usr=012}}
+
{{tp|p=32613971|t=2020. Construction and immunogenic studies of a mFc fusion receptor binding domain (RBD) of spike protein as a subunit vaccine against SARS-CoV-2 infection.|pdf=|usr=012}}
+
{{tp|p=32621392|t=2020. Low serum 25-hydroxyvitamin D (25[OH]D) levels in patients hospitalised with COVID-19 are associated with greater disease severity.|pdf=|usr=012}}
+
{{tp|p=32640049|t=2020. Immune checkpoint inhibition in the era of COVID-19.|pdf=|usr=012}}
+
{{tp|p=32640019|t=2020. Proposing minimum requirements for announcing clinical trial results during the COVID-19 pandemic.|pdf=|usr=012}}
+
{{tp|p=32628748|t=2020. Evaluating use cases for human challenge trials in accelerating SARS-CoV-2 vaccine development.|pdf=|usr=012}}
+
{{tp|p=32648959|t=2020. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review.|pdf=|usr=012}}
+
{{tp|p=32634894|t=2020. Smoking in critically ill patients with COVID-19: the Australian experience.|pdf=|usr=012}}
+
{{tp|p=32628049|t=2020. Analytical Methods on Determination in Pharmaceuticals and Biological Materials of Chloroquine as Available for the Treatment of COVID-19.|pdf=|usr=012}}
+
{{tp|p=32619167|t=2020. Effect of the Phytochemical Agents Against the SARS-CoV and Selected Some of them for Application to COVID-19: A Mini-Review.|pdf=|usr=012}}
+
{{tp|p=32634080|t=2020. Repurposing Drugs for the Management of Patients with Confirmed Coronavirus Disease 2019 (COVID-19).|pdf=|usr=012}}
+
{{tp|p=32634079|t=2020. The role of Chloroquine and Hydroxychloroquine in Immune Regulation and Diseases.|pdf=|usr=012}}
+
{{tp|p=32628591|t=2020. Elucidating the Pivotal Role of Immune Players in the Management of COVID-19: Focus on Mesenchymal Stem Cells and Inflammation.|pdf=|usr=012}}
+
{{tp|p=32648845|t=2020. Therapeutic targets and computational approaches on drug development for COVID-19.|pdf=|usr=012}}
+
{{tp|p=32621718|t=2020. Shape-based Machine Learning Models for the potential Novel COVID-19 protease inhibitors assisted by Molecular Dynamics Simulation.|pdf=|usr=012}}
+
{{tp|p=32643448|t=2020. Network pharmacology and molecular docking analysis on molecular targets and mechanisms of Huashi Baidu formula in the treatment of COVID-19.|pdf=|usr=012}}
+
{{tp|p=32632960|t=2020. Revisiting potential druggable targets against SARS-CoV-2 and repurposing therapeutics under preclinical study and clinical trials: A comprehensive review.|pdf=|usr=012}}
+
{{tp|p=32629169|t=2020. Repositioning chloroquine as antiviral prophylaxis against COVID-19: potential and challenges.|pdf=|usr=012}}
+
{{tp|p=32616659|t=2020. BET 2: Hydroxychloroquine in the treatment of COVID-19.|pdf=|usr=012}}
+
{{tp|p=32616658|t=2020. BET 1: Lopinavir-ritonavir and COVID-19.|pdf=|usr=012}}
+
{{tp|p=32641191|t=2020. Bacillus Calmette-Guerin vaccination and clinical characteristics and outcomes of COVID-19 in Rhode Island, United States: a cohort study.|pdf=|usr=012}}
+
{{tp|p=32648935|t=2020. SGLT2 inhibition and COVID-19: The road not taken.|pdf=|usr=012}}
+
{{tp|p=32620680|t=2020. Do psychotropic drugs used during COVID-19 therapy have an effect on the treatment process?|pdf=|usr=012}}
+
{{tp|p=32631083|t=2020. Repurposing of well-known medications as antivirals: hydroxychloroquine and chloroquine - from HIV-1 infection to COVID-19.|pdf=|usr=012}}
+
{{tp|p=32643980|t=2020. Predictor of poor prognosis of COVID-19 patients----liver injury.|pdf=|usr=012}}
+
{{tp|p=32649840|t=2020. Liver injury in severe COVID-19 infection: current insights and challenges.|pdf=|usr=012}}
+
{{tp|p=32639083|t=2020. Balancing infection control and frailty prevention during and after the COVID-19 pandemic: Introduction of the NCGG Home Exercise Program for Older People 2020.|pdf=|usr=012}}
+
{{tp|p=32645727|t=2020. Isopathic Remedy Prepared from Convalescent Plasma as a Therapeutic Option for COVID-19?|pdf=|usr=012}}
+
{{tp|p=32643512|t=2020. Thinking more about therapy with convalescent plasma for COVID-19 patients.|pdf=|usr=012}}
+
{{tp|p=32633162|t=2020. Successful Treatment of Covid-19 Associated Cytokine Release Syndrome with Colchicine. A Case Report and Review of Literature.|pdf=|usr=012}}
+
{{tp|p=32643997|t=2020. Effect of recombinant human granulocyte colony-stimulating factor on lymphocyte subsets in patients with COVID-19.|pdf=|usr=012}}
+
{{tp|p=32615877|t=2020. Suggestions for Combatting COVID-19 by Natural Means in the Absence of Standard Medical Regimens.|pdf=|usr=012}}
+
{{tp|p=32649272|t=2020. Combating COVID-19 and Building Immune Resilience: A Potential Role for Magnesium Nutrition?|pdf=|usr=012}}
+
{{tp|p=32643552|t=2020. Identification of bioactive molecule from Withania somnifera (Ashwagandha) as SARS-CoV-2 main protease inhibitor.|pdf=|usr=012}}
+
{{tp|p=32643550|t=2020. Potential of NO donor furoxan as SARS-CoV-2 main protease (M(pro)) inhibitors: in silico analysis.|pdf=|usr=012}}
+
{{tp|p=32643529|t=2020. Natural-like products as potential SARS-CoV-2 M(pro) inhibitors: in-silico drug discovery.|pdf=|usr=012}}
+
{{tp|p=32627715|t=2020. Screening of phytochemical compounds of Tinospora cordifolia for their inhibitory activity on SARS-CoV-2: an in silico study.|pdf=|usr=012}}
+
{{tp|p=32627689|t=2020. Possibility of HIV-1 protease inhibitors-clinical trial drugs as repurposed drugs for SARS-CoV-2 main protease: a molecular docking, molecular dynamics and binding free energy simulation study.|pdf=|usr=012}}
+
{{tp|p=32619162|t=2020. Bacterial protein azurin and derived peptides as potential anti-SARS-CoV-2 agents: insights from molecular docking and molecular dynamics simulations.|pdf=|usr=012}}
+
{{tp|p=32619134|t=2020. Epitope based peptide vaccine against SARS-COV2: an immune-informatics approach.|pdf=|usr=012}}
+
{{tp|p=32618198|t=2020. Incretin-Based Therapies Role in COVID-19 Era: Evolving Insights.|pdf=|usr=012}}
+
{{tp|p=32643158|t=2020. Excavating SARS-coronavirus 2 genome for epitope-based subunit vaccine synthesis using immunoinformatics approach.|pdf=|usr=012}}
+
{{tp|p=32643200|t=2020. Convalescent plasma therapy in patients with COVID-19.|pdf=|usr=012}}
+
{{tp|p=32647045|t=2020. Hydroxychloroquine and COVID-19: critiquing the impact of disease public profile on policy and clinical decision-making.|pdf=|usr=012}}
+
{{tp|p=32644254|t=2020. Early use of tocilizumab in the prevention of adult respiratory failure in SARS-CoV-2 infections and the utilization of interleukin-6 levels in the management.|pdf=|usr=012}}
+
{{tp|p=32644224|t=2020. Chronic treatment with hydroxychloroquine and SARS-CoV-2 infection.|pdf=|usr=012}}
+
{{tp|p=32644208|t=2020. Erythropoietin Induced Hemoglobin Sub-Unit Beta may Stimulate Innate Immune RNA Virus Pattern Recognition, Suppress Reactive Oxygen Species, Reduce ACE2 Viral Doorway Opening and Neutrophil Extracellular Traps against Covid-19.|pdf=|usr=012}}
+
{{tp|p=32633865|t=2020. A retrospective review of memantine use and COVID-19-associated mortality from a national database.|pdf=|usr=012}}
+
{{tp|p=32633831|t=2020. RNA-dependent RNA Polymerase of SARS-CoV-2 as a Therapeutic Target.|pdf=|usr=012}}
+
{{tp|p=32621621|t=2020. Lopinavir/ritonavir is associated with pneumonia resolution in COVID-19 patients with influenza coinfection: a retrospective matched-pair cohort study.|pdf=|usr=012}}
+
{{tp|p=32617989|t=2020. Efficacy and safety of umifenovir for coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis.|pdf=|usr=012}}
+
  
{{tp|p=32634602|t=2020. Corticosteroid therapy for patients with CoVID-19 pneumonia: a before-after study.|pdf=|usr=012}}
+
=======================================================================================
{{tp|p=32629115|t=2020. A pharmacological perspective of Chloroquine in SARS-CoV-2 infection.|pdf=|usr=012}}
+
{{tp|p=32619764|t=2020. Case reports study of the first five patients COVID-19 treated with remdesivir in France.|pdf=|usr=012}}
+
{{tp|p=32634589|t=2020. Potential effective treatment for COVID-19: systematic review and meta-analysis of the severe infectious disease with convalescent plasma therapy.|pdf=|usr=012}}
+
{{tp|p=32623082|t=2020. Treatment with Hydroxychloroquine, Azithromycin, and Combination in Patients Hospitalized with COVID-19.|pdf=|usr=012}}
+
{{tp|p=32623080|t=2020. An Observational Cohort Study of Hydroxychloroquine and Azithromycin for COVID-19: (Can't Get No) Satisfaction.|pdf=|usr=012}}
+
{{tp|p=32629817|t=2020. Influence of Herbal Medicines on HMGB1 Release, SARS-CoV-2 Viral Attachment, Acute Respiratory Failure, and Sepsis. A Literature Review.|pdf=|usr=012}}
+
{{tp|p=32617855|t=2020. Phylogenetic Analysis and Structural Perspectives of RNA-Dependent RNA-Polymerase Inhibition from SARs-CoV-2 with Natural Products.|pdf=|usr=012}}
+
{{tp|p=32627127|t=2020. Clinical guidance for navigating the QTc-prolonging and arrhythmogenic potential of pharmacotherapy during the COVID-19 pandemic.|pdf=|usr=012}}
+
{{tp|p=32623068|t=2020. Nucleic Acid Approaches to Antibody-based Therapeutics for COVID-19: A Perspective.|pdf=|usr=012}}
+
{{tp|p=32634126|t=2020. SARS-CoV-2 viral load and antibody responses: the case for convalescent plasma therapy.|pdf=|usr=012}}
+
{{tp|p=32629768|t=2020. Role of Lopinavir/Ritonavir in the Treatment of Covid-19: A Review of Current Evidence, Guideline Recommendations, and Perspectives.|pdf=|usr=012}}
+
{{tp|p=32630746|t=2020. SARS-CoV-2: Repurposed Drugs and Novel Therapeutic Approaches-Insights into Chemical Structure-Biological Activity and Toxicological Screening.|pdf=|usr=012}}
+
{{tp|p=32622963|t=2020. Mesenchymal stromal cells and their secreted extracellular vesicles as therapeutic tools for COVID-19 pneumonia? ().|pdf=|usr=012}}
+
{{tp|p=32622008|t=2020. Azithromycin and SARS-CoV-2 infection: where we are now and where we are going.|pdf=|usr=012}}
+
{{tp|p=32636240|t=2020. BCG vaccine and COVID-19: implications for infection prophylaxis and cancer immunotherapy.|pdf=|usr=012}}
+
{{tp|p=32611687|t=2020. On the use of immune checkpoint inhibitors in patients with viral infections including COVID-19.|pdf=|usr=012}}
+
{{tp|p=32627442|t=2020. Convalescent Plasma Therapy in Coronavirus Disease 2019: a Case Report and Suggestions to Overcome Obstacles.|pdf=|usr=012}}
+
{{tp|p=32638109|t=2020. Mild COVID-19 infection in an NMO patient treated with tocilizumab: a confirmation of anti-IL-6 protective role?|pdf=|usr=012}}
+
{{tp|p=32646487|t=2020. Evolving geographic diversity in SARS-CoV2 and in silico analysis of replicating enzyme 3CL(pro) targeting repurposed drug candidates.|pdf=|usr=012}}
+
{{tp|p=32635935|t=2020. Analysis of SARS-CoV-2 RNA-dependent RNA polymerase as a potential therapeutic drug target using a computational approach.|pdf=|usr=012}}
+
{{tp|p=32631442|t=2020. Systematic review of the registered clinical trials for coronavirus disease 2019 (COVID-19).|pdf=|usr=012}}
+
{{tp|p=32650019|t=2020. Interleukin 6 levels after tocilizumab administration in transplant recipients with COVID-19.|pdf=|usr=012}}
+
{{tp|p=32629788|t=2020. Calcineurin Inhibitor-Based Immunosuppression and COVID-19: Results from a Multidisciplinary Cohort of Patients in Northern Italy.|pdf=|usr=012}}
+
{{tp|p=32610445|t=2020. Microbial Natural Products as Potential Inhibitors of SARS-CoV-2 Main Protease (M(pro)).|pdf=|usr=012}}
+
{{tp|p=32634550|t=2020. Aptamers, the bivalent agents as probes and therapies for coronavirus infections: A systematic review.|pdf=|usr=012}}
+
{{tp|p=32641037|t=2020. Caspase1/11 signaling affects muscle regeneration and recovery following ischemia, and can be modulated by chloroquine.|pdf=|usr=012}}
+
{{tp|p=32647131|t=2020. Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice.|pdf=|usr=012}}
+
{{tp|p=32648153|t=2020. The risk of QTc-interval prolongation in COVID-19 patients treated with chloroquine.|pdf=|usr=012}}
+
{{tp|p=32641560|t=2020. COVID-19 and vitamin D deficiency, a fatal combination?|pdf=|usr=012}}
+
{{tp|p=32645974|t=2020. SARS-CoV-2, ACE2, and Hydroxychloroquine: Cardiovascular Complications, Therapeutics, and Clinical Readouts in the Current Settings.|pdf=|usr=012}}
+
{{tp|p=32619723|t=2020. Edaravone: A potential treatment for the COVID-19-induced inflammatory syndrome?|pdf=|usr=012}}
+
{{tp|p=32622723|t=2020. Chinese herbal medicine for coronavirus disease 2019: A systematic review and meta-analysis.|pdf=|usr=012}}
+
{{tp|p=32629137|t=2020. Ultraviolet-based Biophotonic Technologies and COVID-19.|pdf=|usr=012}}
+
{{tp|p=32641511|t=2020. Discovery of potent thrombin inhibitors from a protease-focused DNA-encoded chemical library.|pdf=|usr=012}}
+
{{tp|p=32621829|t=2020. Letter to the editor regarding "Lack of supporting data make the risks of a clinical trial of radiation therapy as a treatment for COVID-19 pneumonia unacceptable".|pdf=|usr=012}}
+
{{tp|p=32638884|t=2020. Primum non nocere - Are chloroquine and hydroxychloroquine safe prophylactic/treatment options for SARS-CoV-2 (covid-19)?|pdf=|usr=012}}
+
{{tp|p=32616763|t=2020. A candidate multi-epitope vaccine against SARS-CoV-2.|pdf=|usr=012}}
+
{{tp|p=32638647|t=2020. Alternative management of Covid-19 infection.|pdf=|usr=012}}
+
{{tp|p=32636116|t=2020. First case of convalescent plasma transfusion in a child with COVID-19-associated severe aplastic anemia.|pdf=|usr=012}}
+
{{tp|p=32645478|t=2020. Hydroxychloroquine safety: A meta-analysis of randomized controlled trials.|pdf=|usr=012}}
+
{{tp|p=32629139|t=2020. No evidence of clinical benefits of early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: Comment on "Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France".|pdf=|usr=012}}
+
{{tp|p=32635353|t=2020. Treatment of Severe COVID-19 with Tocilizumab Mitigates Cytokine Storm and Averts Mechanical Ventilation During Acute Respiratory Distress: A Case Report and Literature Review.|pdf=|usr=012}}
+
{{tp|p=32640619|t=2020. Prospects and Challenges in the Development of Universal Influenza Vaccines.|pdf=|usr=012}}
+
{{tp|p=32635180|t=2020. Immunoinformatic Analysis of T- and B-Cell Epitopes for SARS-CoV-2 Vaccine Design.|pdf=|usr=012}}
+
{{tp|p=32621841|t=2020. Epitope-based peptide vaccines predicted against novel coronavirus disease caused by SARS-CoV-2.|pdf=|usr=012}}
+
{{tp|p=32629804|t=2020. Repurposing Therapeutics for Potential Treatment of SARS-CoV-2: A Review.|pdf=|usr=012}}
+
{{tp|p=32620700|t=2020. Low Dose Radiation to COVID-19 Patients to Ease the Disease Course and Reduce the Need of Intensive Care.|pdf=|usr=012}}
+
{{tp|p=32623965|t=2020. Are we aware of potential interactions between drugs used in lung cancer and drugs used in the treatment of COVID-19?|pdf=|usr=012}}
+
{{tp|p=32628262|t=2020. The Development of COVID-19 Vaccines: Safeguards Needed.|pdf=|usr=012}}
+
{{tp|p=32628244|t=2020. Developing a SARS-CoV-2 Vaccine at Warp Speed.|pdf=|usr=012}}
+
{{tp|p=32614442|t=2020. Evolution of Altered Sense of Smell or Taste in Patients With Mildly Symptomatic COVID-19.|pdf=|usr=012}}
+
{{tp|p=32613691|t=2020. Editorial - Nutritional Status Affects COVID-19 Patient Outcomes.|pdf=|usr=012}}
+
{{tp|p=32613660|t=2020. Evaluation of Nutritional Risk and its Association With Mortality Risk in Severe and Critically Ill COVID-19 Patients.|pdf=|usr=012}}
+
{{tp|p=32619276|t=2020. Low dose radiation as a treatment for COVID-19 pneumonia: a threat or real opportunity?|pdf=|usr=012}}
+
{{tp|p=32619669|t=2020. Virtual screening based on molecular docking of possible inhibitors of Covid-19 main protease.|pdf=|usr=012}}
+
{{tp|p=32633860|t=2020. Safety of Plasma Infusions in Parkinson's Disease.|pdf=|usr=012}}
+
{{tp|p=32649078|t=2020. Remdesivir for the Treatment of Covid-19 - Preliminary Report. Reply.|pdf=|usr=012}}
+
{{tp|p=32649077|t=2020. Remdesivir for the Treatment of Covid-19 - Preliminary Report.|pdf=|usr=012}}
+
{{tp|p=32649076|t=2020. Remdesivir for the Treatment of Covid-19 - Preliminary Report.|pdf=|usr=012}}
+
{{tp|p=32649075|t=2020. Remdesivir for the Treatment of Covid-19 - Preliminary Report.|pdf=|usr=012}}
+
{{tp|p=32649074|t=2020. Remdesivir for the Treatment of Covid-19 - Preliminary Report.|pdf=|usr=012}}
+
{{tp|p=32643410|t=2020. Bioactive compounds from marine resources against novel corona virus (2019-nCoV): in silico study for corona viral drug.|pdf=|usr=012}}
+
{{tp|p=32636505|t=2020. COVID-19 platform trial delivers.|pdf=|usr=012}}
+
{{tp|p=32623442|t=2020. Going back in time for an antibody to fight COVID-19.|pdf=|usr=012}}
+
{{tp|p=32645305|t=2020. Golden Anniversary of the Nicotinic Receptor.|pdf=|usr=012}}
+
{{tp|p=32618794|t=2020. Tocilizumab and Remdesivir in a Pregnant Patient With Coronavirus Disease 2019 (COVID-19).|pdf=|usr=012}}
+
{{tp|p=32615642|t=2020. Is povidone-iodine mouthwash effective against SARS-CoV-2? First in vivo tests.|pdf=|usr=012}}
+
{{tp|p=32613637|t=2020. Naringenin, a flavanone with antiviral and anti-inflammatory effects: A promising treatment strategy against COVID-19.|pdf=|usr=012}}
+
{{tp|p=32648294|t=2020. COVID-19: Phylogenetic approaches may help in finding resources for natural cure.|pdf=|usr=012}}
+
{{tp|p=32647056|t=2020. BCG vaccine protection from severe coronavirus disease 2019 (COVID-19).|pdf=|usr=012}}
+
{{tp|p=32648313|t=2020. Immunopathology and immunotherapeutic strategies in severe acute respiratory syndrome coronavirus 2 infection.|pdf=|usr=012}}
+
{{tp|p=32614102|t=2020. Using heat to kill SARS-CoV-2.|pdf=|usr=012}}
+
{{tp|p=32646977|t=2020. Can interferons stop COVID-19 before it takes hold?|pdf=|usr=012}}
+
{{tp|p=32649367|t=2020. Potential Immunotherapeutic Targets For Hypoxia Due to COVI-FLU.|pdf=|usr=012}}
+
{{tp|p=32619318|t=2020. COVID-19 drug repurposing: Summary statistics on current clinical trials and promising untested candidates.|pdf=|usr=012}}
+
{{tp|p=32627216|t=2020. Characteristics and serological patterns of COVID-19 convalescent plasma donors: optimal donors and timing of donation.|pdf=|usr=012}}
+
{{tp|p=32639598|t=2020. SARS-CoV2 and immunosuppression: a double-edged sword.|pdf=|usr=012}}
+
{{tp|p=32629531|t=2020. Severe COVID-19 in a patient with chronic graft-versus-host disease after hematopoietic stem cell transplant successfully treated with ruxolitinib.|pdf=|usr=012}}
+
{{tp|p=32614684|t=2020. Review of the SARS-CoV-2 in Wuhan and Analysis as Well as Prediction of Therapeutic Drugs.|pdf=|usr=012}}
+
  
{{tp|p=32388537|t=2020. Designing of improved drugs for COVID-19: Crystal structure of SARS-CoV-2 main protease M(pro).|pdf=|usr=009}}
+
COVID19 is now a CURABLE disease !!!
{{tp|p=32532959|t=2020. The role of furin cleavage site in SARS-CoV-2 spike protein-mediated membrane fusion in the presence or absence of trypsin.|pdf=|usr=009}}
+
{{tp|p=32423553|t=2020. Angiotensin converting enzyme: A review on expression profile and its association with human disorders with special focus on SARS-CoV-2 infection.|pdf=|usr=009}}
+
{{tp|p=32531235|t=2020. Role of the GTNGTKR motif in the N-terminal receptor-binding domain of the SARS-CoV-2 spike protein.|pdf=|usr=009}}
+
{{tp|p=32430279|t=2020. Gut microbiota and Covid-19- possible link and implications.|pdf=|usr=009}}
+
{{tp|p=32416259|t=2020. On the interactions of the receptor-binding domain of SARS-CoV-1 and SARS-CoV-2 spike proteins with monoclonal antibodies and the receptor ACE2.|pdf=|usr=009}}
+
{{tp|p=32558150|t=2020. Individual variation of the SARS-CoV-2 receptor ACE2 gene expression and regulation.|pdf=|usr=010}}
+
{{tp|p=32585135|t=2020. Neutralization of SARS-CoV-2 by Destruction of the Prefusion Spike.|pdf=|usr=010}}
+
{{tp|p=32546195|t=2020. Micronutrient status of COVID-19 patients: a critical consideration.|pdf=|usr=010}}
+
{{tp|p=32559343|t=2020. Rationale for targeting Complement in COVID-19.|pdf=|usr=010}}
+
{{tp|p=32543705|t=2020. Evolutionary relationships and sequence-structure determinants in human SARS coronavirus-2 spike proteins for host receptor recognition.|pdf=|usr=010}}
+
{{tp|p=32592394|t=2020. A role for selenium-dependent GPX1 in SARS-CoV-2 virulence.|pdf=|usr=010}}
+
{{tp|p=32590326|t=2020. Pulmonary surfactant itself must be a strong defender against SARS-CoV-2.|pdf=|usr=010}}
+
{{tp|p=32562814|t=2020. Statins and other drugs: Facing COVID-19 as a vascular disease.|pdf=|usr=010}}
+
{{tp|p=32424591|t=2020. COVID-19, acute respiratory distress syndrome (ARDS), and hyperbaric oxygen therapy (HBOT): what is the link?|pdf=|usr=011}}
+
{{tp|p=32598884|t=2020. Alterations in Fecal Fungal Microbiome of Patients With COVID-19 During Time of Hospitalization until Discharge.|pdf=|usr=011}}
+
{{tp|p=32481719|t=2020. The Role of MicroRNA in the Airway Surface Liquid Homeostasis.|pdf=|usr=011}}
+
{{tp|p=32534506|t=2020. Bradykinin as a Probable Aspect in SARS-Cov-2 Scenarios: Is Bradykinin Sneaking out of Our Sight?|pdf=|usr=011}}
+
{{tp|p=32600316|t=2020. The cholinergic anti-inflammatory pathway alleviates acute lung injury.|pdf=|usr=011}}
+
{{tp|p=32537478|t=2020. Airways Expression of SARS-CoV-2 Receptor, ACE2, and TMPRSS2 Is Lower in Children Than Adults and Increases with Smoking and COPD.|pdf=|usr=011}}
+
{{tp|p=32595361|t=2020. Gut-lung axis and dysbiosis in COVID-19.|pdf=|usr=011}}
+
{{tp|p=32591496|t=2020. Door to the cell for COVID-19 opened, leading way to therapies.|pdf=|usr=011}}
+
{{tp|p=32602262|t=2020. Use of Anakinra to Prevent Mechanical Ventilation in Severe COVID-19: A Case Series.|pdf=|usr=011}}
+
{{tp|p=32555145|t=2020. Targeting the entry step of SARS-CoV-2: a promising therapeutic approach.|pdf=|usr=011}}
+
{{tp|p=32594085|t=2020. Early Hemoperfusion for Cytokine Removal May Contribute to Prevention of Intubation in Patients Infected with COVID-19.|pdf=|usr=011}}
+
{{tp|p=32582574|t=2020. ACE2, Much More Than Just a Receptor for SARS-COV-2.|pdf=|usr=011}}
+
{{tp|p=32545271|t=2020. Relative Abundance of SARS-CoV-2 Entry Genes in the Enterocytes of the Lower Gastrointestinal Tract.|pdf=|usr=011}}
+
{{ttp|p=32593832|t=2020. Why is SARS-CoV-2 infection more severe in obese men? The gut lymphatics - Lung axis hypothesis.|pdf=|usr=011}}
+
{{tp|p=32573788|t=2020. Elucidation of Cellular Targets and Exploitation of the Receptor Binding Domain of SARS-CoV-2 for vaccine and monoclonal antibody synthesis.|pdf=|usr=011}}
+
{{tp|p=32551652|t=2020. Critical Differences Between the Binding Features of the Spike Proteins of SARS-CoV-2 and SARS-CoV.|pdf=|usr=011}}
+
{{tp|p=32551648|t=2020. The Discovery of a Putative Allosteric Site in the SARS-CoV-2 Spike Protein Using an Integrated Structural/Dynamic Approach.|pdf=|usr=011}}
+
{{tp|p=32571797|t=2020. Identification of common deletions in the spike protein of SARS-CoV-2.|pdf=|usr=011}}
+
{{tp|p=32606248|t=2020. Genomic discovery of an evolutionarily programmed modality for small-molecule targeting of an intractable protein surface.|pdf=|usr=011}}
+
{{tp|p=32602627|t=2020. Angiotensin-converting enzyme 2: The old door for new severe acute respiratory syndrome coronavirus 2 infection.|pdf=|usr=011}}
+
  
{{tp|p=32417594|t=2020. Supplements for COVID-19: A modifiable environmental risk.|pdf=|usr=011}}
+
=======================================================================================

Aktuelle Version vom 21. September 2021, 06:15 Uhr

homepage
hottest actual papers
 P further streaming-in related content is here
 CHERRYPICKING STUDIES IS NOT SCIENCE
Reviews on covid drug development


PHA related options:


A concept of curative retargeting has been found by cellular lockdown with kinase inhibitors from the oncologic pharmacopoiea.
This means, virus replication can be stalled to zero w/o need of develpoment of new substances. There is no need for world
vaccination anymore. The virus needs permissible cells, and most perimissible is phosphotyrosine on its own compnents.
Paper is (not yet in PubMed) :

credentials to Marinus Brandl who told us about it today. based on e.g.

32408336 2020. Proteomics of SARS-CoV-2-infected host cells reveals therapy targets
=======================================================================================
COVID19 is now a CURABLE disease !!!
=======================================================================================

Meine Werkzeuge
Namensräume
Varianten
Aktionen
Navigation
Werkzeuge
Blogverzeichnis - Blog Verzeichnis bloggerei.deBlogverzeichnis